Health professionals are encouraged to take the ESC Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

ESC Guidelines 3002 recommendations. To implement the guidelines, condensed pocket
guidelines versions, summary slides, booklets with essential messages, and an electronic …

Background Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate
receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition …

Surveys and registries are needed to verify that real-life daily practice is in keeping with
what is recommended in the guidelines, thus completing the loop between clinical research, …

Background The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial
infarction has not been established. We investigated the efficacy and safety of ticagrelor, a …

Background— Ticagrelor is the first reversibly binding oral P2Y 12 receptor antagonist. This
is the first study to compare the onset and offset of platelet inhibition (IPA) with ticagrelor …

Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall and to
thrombosis is the foremost cause of premature mortality and of disability-adjusted life years (…

Background Vorapaxar is a new oral protease-activated–receptor 1 (PAR-1) antagonist that
inhibits thrombin-induced platelet activation. Methods In this multinational, double-blind, …

Background Appropriate antithrombotic regimens for patients with atrial fibrillation who have
an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) …

Background Variation in and irreversibility of platelet inhibition with clopidogrel has led to
controversy about its optimum dose and timing of administration in patients with acute coronary …